These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26806010)

  • 1. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
    De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
    Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
    Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
    Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
    Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
    Pivot X; Gligorov J; Müller V; Curigliano G; Knoop A; Verma S; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Ann Oncol; 2014 Oct; 25(10):1979-1987. PubMed ID: 25070545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
    Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
    Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
    Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
    Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
    Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial.
    Kaidarova D; Zhavrid E; Shatkovskaya O; Prokharau A; Akhmed N; Sembayev D; Rutzhanova Z; Ivankov A
    Cancer Treat Res Commun; 2024; 40():100817. PubMed ID: 38735220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
    Fallowfield L; Osborne S; Langridge C; Monson K; Kilkerr J; Jenkins V
    Breast; 2015 Apr; 24(2):166-70. PubMed ID: 25623753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
    Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
    Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
    Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
    Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
    Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
    Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
    Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
    De Cock E; Kritikou P; Sandoval M; Tao S; Wiesner C; Carella AM; Ngoh C; Waterboer T
    PLoS One; 2016; 11(6):e0157957. PubMed ID: 27362533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    Zambetti M; Montemurro F; Morandi P; Zamagni C; Brandes AA; Bisagni G; Cagossi K; Bengala C; Gori S; Iannacone C; Stell A; Gianni L
    Eur J Cancer; 2018 Dec; 105():61-70. PubMed ID: 30396014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
    Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
    J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.